Tyrosine kinase inhibition: A therapeutic target for the management of chronic-phase chronic myeloid leukemia

Elias J. Jabbour, Jorge E. Cortes, Hagop M. Kantarjian

Research output: Contribution to journalReview article

Abstract

Chronic myeloid leukemia (CML) is a hematologic neoplasm with a progressive, ultimately terminal, disease course. In most cases, CML arises owing to the aberrant formation of a chimeric gene for a constitutively active tyrosine kinase. Inhibition of the signaling activity of this kinase has proved to be a highly successful treatment target, transforming the prognosis of patients with CML. New tyrosine kinase inhibitors continue to improve the management of CML, offering alternative options for those resistant to or intolerant of standard tyrosine kinase inhibitors. Here we review the pathobiology of CML and explore emerging strategies to optimize the management of chronic-phase CML, particularly first-line treatment.

Original languageEnglish (US)
Pages (from-to)1433-1452
Number of pages20
JournalExpert Review of Anticancer Therapy
Volume13
Issue number12
DOIs
StatePublished - Nov 29 2013
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Therapeutics
Hematologic Neoplasms
Phosphotransferases
Genes

Keywords

  • Chronic myeloid leukemia
  • Molecular response
  • Suboptimal response
  • Tyrosine kinase inhibition

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Tyrosine kinase inhibition : A therapeutic target for the management of chronic-phase chronic myeloid leukemia. / Jabbour, Elias J.; Cortes, Jorge E.; Kantarjian, Hagop M.

In: Expert Review of Anticancer Therapy, Vol. 13, No. 12, 29.11.2013, p. 1433-1452.

Research output: Contribution to journalReview article

@article{ae3395fc5ab940f5ac6f45ec206ec55c,
title = "Tyrosine kinase inhibition: A therapeutic target for the management of chronic-phase chronic myeloid leukemia",
abstract = "Chronic myeloid leukemia (CML) is a hematologic neoplasm with a progressive, ultimately terminal, disease course. In most cases, CML arises owing to the aberrant formation of a chimeric gene for a constitutively active tyrosine kinase. Inhibition of the signaling activity of this kinase has proved to be a highly successful treatment target, transforming the prognosis of patients with CML. New tyrosine kinase inhibitors continue to improve the management of CML, offering alternative options for those resistant to or intolerant of standard tyrosine kinase inhibitors. Here we review the pathobiology of CML and explore emerging strategies to optimize the management of chronic-phase CML, particularly first-line treatment.",
keywords = "Chronic myeloid leukemia, Molecular response, Suboptimal response, Tyrosine kinase inhibition",
author = "Jabbour, {Elias J.} and Cortes, {Jorge E.} and Kantarjian, {Hagop M.}",
year = "2013",
month = "11",
day = "29",
doi = "10.1586/14737140.2013.859074",
language = "English (US)",
volume = "13",
pages = "1433--1452",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Tyrosine kinase inhibition

T2 - A therapeutic target for the management of chronic-phase chronic myeloid leukemia

AU - Jabbour, Elias J.

AU - Cortes, Jorge E.

AU - Kantarjian, Hagop M.

PY - 2013/11/29

Y1 - 2013/11/29

N2 - Chronic myeloid leukemia (CML) is a hematologic neoplasm with a progressive, ultimately terminal, disease course. In most cases, CML arises owing to the aberrant formation of a chimeric gene for a constitutively active tyrosine kinase. Inhibition of the signaling activity of this kinase has proved to be a highly successful treatment target, transforming the prognosis of patients with CML. New tyrosine kinase inhibitors continue to improve the management of CML, offering alternative options for those resistant to or intolerant of standard tyrosine kinase inhibitors. Here we review the pathobiology of CML and explore emerging strategies to optimize the management of chronic-phase CML, particularly first-line treatment.

AB - Chronic myeloid leukemia (CML) is a hematologic neoplasm with a progressive, ultimately terminal, disease course. In most cases, CML arises owing to the aberrant formation of a chimeric gene for a constitutively active tyrosine kinase. Inhibition of the signaling activity of this kinase has proved to be a highly successful treatment target, transforming the prognosis of patients with CML. New tyrosine kinase inhibitors continue to improve the management of CML, offering alternative options for those resistant to or intolerant of standard tyrosine kinase inhibitors. Here we review the pathobiology of CML and explore emerging strategies to optimize the management of chronic-phase CML, particularly first-line treatment.

KW - Chronic myeloid leukemia

KW - Molecular response

KW - Suboptimal response

KW - Tyrosine kinase inhibition

UR - http://www.scopus.com/inward/record.url?scp=84888263504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888263504&partnerID=8YFLogxK

U2 - 10.1586/14737140.2013.859074

DO - 10.1586/14737140.2013.859074

M3 - Review article

C2 - 24236822

AN - SCOPUS:84888263504

VL - 13

SP - 1433

EP - 1452

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 12

ER -